SUMMARY
Individuals can test positive for SARS-CoV-2 by real-time polymerase chain reaction (RT-PCR) after no longer being infectious.1-8 Positive SARS-CoV-2 antigen-based testing exhibits a temporal pattern that corresponds with active, replicating virus and could therefore be a more accurate predictor of an individual’s potential to transmit SARS-CoV-2.2,3,9 Using the BD Veritor System for Rapid Detection of SARS-CoV-2 later flow antigen detection test, we demonstrate a higher concordance of antigen-positive test results with the presence of cultured, infectious virus when compared to RT-PCR. When compared to infectious virus isolation, the sensitivity of antigen-based testing is similar to RT-PCR. The correlation between SARS-CoV-2 antigen and SARS-CoV-2 culture represents a significant advancement in determining the risk for potential transmissibility beyond that which can be achieved by detection of SARS-CoV-2 genomic RNA. Coupled with a rapid time-to-result, low cost, and scalability, antigen-based testing should facilitate effective implementation of testing and public health interventions that will better contain COVID-19.
Competing Interest Statement
CKC, VP, JCA, SK, JL, DSG, and CR-D are employees of Becton, Dickinson and Company. AP, ML, and YM received research funds to support their work for this study.
Clinical Trial
Registration of this study at ClinicalTrials.gov was not obtained as it did not fulfill the applicable minimum medical device clinical trial requirement criteria as per the Food and Drug Administration Amendments Act. Specifically, this study did not assess health outcomes associated with the use of this assay.
Funding Statement
This study was funded by Becton, Dickinson and Company; BD Life Sciences-Integrated Diagnostics Solutions. Non-BD employee authors received research funds to support their work for this study.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Advarra IRBapproval--MOD00683499--29May2020 Becton Dickinson - BDX-GSCP01, Becton Dickinson Program for Collection of BioSpecimens (Pro00015576)
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Requests for data related to this study should be sent to Charles K. Cooper at Becton, Dickinson and Company.
